Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural Ppublish 35 citations
PubMed: 35395068 DOI: 10.1182/bloodadvances.2022006983
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities.
Blood Adv 6(11):3398-3403
Authors: Caroline Diorio, Anant Vatsayan, Aimee C Talleur, Colleen Annesley, Jennifer J Jaroscak, Haneen Shalabi, Amanda K Ombrello, Michelle Hudspeth, Shannon L Maude, Rebecca A Gardner, Nirali N Shah
Affiliations
- Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
- Division of BMT, Children's National Hospital, Washington, DC.
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.
- Department of Pediatrics, Seattle Children's Hospital, Seattle, WA.
- Pediatric Hematology/Oncology, Medical University of South Carolina, Charleston, SC.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and.
- Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
MeSH
Cells, T-Lymphocytes, Hematologic Diseases, Car-T Cell
Cited by
- [Hemophagocytic lymphohistiocytosis following treatment with CAR-T therapy: two cases reports and literature review]. Zhonghua Xue Ye Xue Za Zhi, 2023
- Weal and woe of interleukin-18 in the T cell therapy of cancer. J Immunother Cancer, 2025
- INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities. Transplant Cell Ther, 2024
- Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia, 2025
- CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv, 2024
- Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother, 2022
- How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood, 2023
- Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma. Mol Ther Oncol, 2025
- Applying a clinical lens to animal models of CAR-T cell therapies. Mol Ther Methods Clin Dev, 2022
- Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review). Mol Med Rep, 2025
- Immunotherapy-related neurotoxicity in the central nervous system of children with cancer. Neuro Oncol, 2025
- INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities. Transplant Cell Ther, 2024
- How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood, 2023
- Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol, 2024
- Solid tumour cellular therapy - principles of toxicity management. Immunooncol Technol, 2025
- Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol, 2024
- Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct Target Ther, 2025
- The Multifaceted Immunology of Cytokine Storm Syndrome. J Immunol, 2023
- Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv, 2025